全文获取类型
收费全文 | 6167篇 |
免费 | 515篇 |
国内免费 | 104篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 76篇 |
妇产科学 | 43篇 |
基础医学 | 192篇 |
口腔科学 | 27篇 |
临床医学 | 449篇 |
内科学 | 575篇 |
皮肤病学 | 79篇 |
神经病学 | 327篇 |
特种医学 | 172篇 |
外科学 | 320篇 |
综合类 | 1410篇 |
预防医学 | 569篇 |
眼科学 | 59篇 |
药学 | 1436篇 |
3篇 | |
中国医学 | 633篇 |
肿瘤学 | 385篇 |
出版年
2024年 | 6篇 |
2023年 | 89篇 |
2022年 | 259篇 |
2021年 | 313篇 |
2020年 | 316篇 |
2019年 | 177篇 |
2018年 | 178篇 |
2017年 | 238篇 |
2016年 | 282篇 |
2015年 | 247篇 |
2014年 | 861篇 |
2013年 | 858篇 |
2012年 | 655篇 |
2011年 | 554篇 |
2010年 | 414篇 |
2009年 | 215篇 |
2008年 | 190篇 |
2007年 | 202篇 |
2006年 | 121篇 |
2005年 | 103篇 |
2004年 | 103篇 |
2003年 | 86篇 |
2002年 | 67篇 |
2001年 | 58篇 |
2000年 | 40篇 |
1999年 | 32篇 |
1998年 | 18篇 |
1997年 | 19篇 |
1996年 | 18篇 |
1995年 | 12篇 |
1994年 | 11篇 |
1993年 | 10篇 |
1992年 | 5篇 |
1991年 | 6篇 |
1990年 | 2篇 |
1989年 | 3篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 3篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1974年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有6786条查询结果,搜索用时 31 毫秒
1.
《Vaccine》2022,40(19):2679-2695
Vaccinations are essential for preventing infectious diseases in children with chronic diseases as they have increased risk of infection from frequent use of biologics. Response to immunizations in this group is not well known.ObjectiveA systematic review was performed to evaluate three primary outcomes: efficacy; immunogenicity; and safety of vaccines in children with chronic conditions treated with biologics.MethodsThe protocol for our systematic review and meta-analysis was registered and published with PROSPERO. We searched electronic bibliographic databases for studies published from 2009 to 2019, focusing on vaccinations in children with chronic conditions treated with biologics.ResultsWe retrieved 532 records. Thirty-one full-text articles were selected, and 14 were included in the meta-analysis. No significant publication bias was found. Efficacy: limited data are available regarding the efficacy of vaccination, as most studies have focused on immunogenicity as surrogate outcome for efficacy. Immunogenicity: patients receiving anti-TNF-alpha therapy had a statistically significant risk of poor seroconversion (p = 0.028) and seroprotection by the serotype B influenza vaccine [inflammatory bowel disease (IBD) p = 0.013; juvenile idiopathic arthritis (JIA) p = 0.004]. We found adequate responses with H1N1 and H3N2 serotypes. Few studies existed for pneumococcal, hepatitis A virus, hepatitis B virus, varicella-zoster virus, Measles Mumps Rubella virus, and multiple vaccine administration. Safety: vaccine administration was not associated with serious side effects, but JIA patients on anti-TNF alpha therapy had a statistically significant risk of presenting with myalgia or arthralgia postinfluenza vaccine (p = 0.014).ConclusionsMore evidence concerning efficacy, immunogenicity, and safety of vaccinations is needed to guide physicians in the vaccine decision process for this pediatric population. 相似文献
3.
目的 对已公开发表的新冠肺炎核心指标集及其研究方法进行比较分析,为临床试验和证据转化研究提供参考信息。方法 计算机检索COMET数据库,并补充检索CNKI、WanFang、PubMed、Web of Science、The Cochrane Library等数据库,收集发表的新型冠状病毒肺炎(Coronavirus Disease 2019,COVID-19)核心指标集(Core Outcome Set,COS)研究,检索时间截至为2021年3月31日。按照纳入排除标准筛选文献,并提取研究基本信息、研究方法及指标数据,对其进行描述性分析。结果 共纳入5项COVID-19核心指标集相关研究(4项为COVID-19-COS研究,1项为COVID-19核心指标测量工具研究)。相同的结局指标包括死亡率、病毒核酸检测、临床进展、恢复期、临床症状评分及临床分型等。指标来源主要来自临床试验注册平台和问卷调查;达成共识的方法主要采用共识会议;利益相关群体中临床专家、方法学专家和医疗管理人员涉及较多。结论 不同的新冠肺炎核心指标集研究有一定的共性,但由于应用场景不同,也存在一定差异。随着对疾病认识的深化,相关COVID-19核心指标需要加强测量方法和疗程推荐。 相似文献
4.
5.
目的比较双孔腹腔镜疝修补术(DSLH)与单孔腹腔镜疝修补术(SSLH)在儿童腹股沟疝微创治疗中的疗效。
方法选取2012年12月至2015年12月间广东医科大学附属医院收治且经B超检查确诊的腹股沟疝患儿178例作为研究对象。其中89例接受DSLH治疗为DSLH组,89例接受SSLH治疗为SSLH组。比较两组患儿的治疗效果(手术时间、术中出血量、住院时间、术后下床活动时间、复发率)以及术后并发症的发生情况。
结果相较DSLH组,SSLH组的手术时间、住院时间显著缩短(t=3.814、4.413,均P<0.001),术后下床活动时间更早(χ2=113.51,P<0.001),术中出血量少(t=4.012,P<0.001);但是两组患儿的复发率及术后并发症的发生率差异无统计学意义(χ2=1.006、0.339,P=0.316、0.560)。
结论SSLH较DSLH治疗效果更好,值得临床推广应用。 相似文献
6.
Benjamin Davido Rui Batista Aurélien Dinh Pierre de Truchis E.M. Terveer Bruce Roberts Ed J. Kuijper Silvia Caballero 《International journal of antimicrobial agents》2019,53(5):553-556
Background
Spontaneous decolonization of antibiotic-resistant bacteria (ARB) takes time: approximately 25% after 30 days for carbapenem-producing Enterobacteriaceae or extended-spectrum beta-lactamase-producing Enterobacteriaceae. Faecal microbiota transplantation (FMT) has been proposed as a new strategy to promote decolonization in order to reduce the risk of superinfection due to these ARB. This paper discusses the literature on the use of FMT for this indication, and the improvement levers available to promote its efficacy.Methods
Literature available to date concerning the use of FMT to eradicate ARB was reviewed, and the different factors that may have influenced the efficacy of decolonization were evaluated.Results
Four axes that could have played major roles in the efficacy of FMT were identified: bowel preparation before FMT; donor; dose; and thermal conditioning of faeces. The positive or negative impact of each on the outcome of FMT is discussed.Conclusion
Although FMT is very efficient for the eradication of Clostridium difficile, the same ‘recipe’ cannot be used for the eradication of ARB. Working together with expert centres may help to improve the efficacy of FMT for this indication, and enable the reduction of in-hospital isolation precautions. 相似文献7.
《Vaccine》2019,37(43):6310-6316
BackgroundSerotype 3 pneumococcal disease has not substantially declined at the population level after the routine introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into pediatric immunization programs across the globe. This epidemiological finding has generated debate regarding the effectiveness of PCV13 against serotype 3 disease. Evaluating PCV13 effectiveness against serotype 3 is especially critical in adults, where serotype 3 makes up an important amount of remaining pneumococcal disease.MethodsWe performed a systematic review of the published literature to assess the direct effectiveness of PCV13 against serotype 3 community-acquired pneumonia (CAP) among adults. We then estimated overall vaccine effectiveness (VE) using a pooled analysis of the individual-level, raw data.ResultsTwo published studies met inclusion criteria. One was a randomized controlled trial conducted in the Netherlands and published in 2014. The other was a recently-published case-control study conducted in Louisville, Kentucky that used a test-negative design (TND). We also identified a third TND study conducted in Argentina that was recently presented as a conference abstract but is not yet published. All three studies were conducted in adults aged ≥65 years. PCV13 VE against serotype 3 hospitalized CAP was 52.5% (95%CI: 6.2–75.9%) from the pooled analysis of individual-level data from all three studies. Results were similar if the unpublished estimate was excluded (serotype 3 VE = 53.6% [95%CI: 6.7–76.9%]). No heterogeneity was observed.ConclusionsCurrently-available evidence, although limited to three studies, suggests that PCV13 provides direct protection against serotype 3 hospitalized CAP in adults aged ≥65 years. 相似文献
8.
目的:系统性评价替格瑞洛对比氯吡格雷治疗东亚急性冠状动脉综合征(ACS)患者的有效性和安全性,旨在为临床用药提供循证参考。方法:计算机检索Cochrane图书馆、PubMed、Embase、中国知网、万方数据库等,收集替格瑞洛(试验组)对比氯吡格雷(对照组)治疗东亚ACS患者的随机对照试验(RCT)。筛选文献、提取数据后采用Cochrane系统评价员手册5.1.0推荐的偏倚风险评估工具对纳入文献进行质量评价,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入5项RCT,共计4511例患者。Meta分析结果显示,两组患者主要心血管不良事件发生率[OR=0.85,95%CI(0.68,1.04),P=0.12]、心血管原因死亡率[OR=0.76,95%CI(0.57,1.03),P=0.08]、脑卒中发生率[OR=0.77,95%CI(0.48,1.24),P=0.28]比较,差异均无统计学意义;试验组患者主要出血事件发生率[OR=1.54,95%CI(1.19,1.99),P=0.001]、次要出血事件发生率[OR=1.80,95%CI(1.40,2.32),P<0.00001]均显著高于对照组。结论:替格瑞洛在降低东亚ACS患者的主要心血管不良事件、心血管原因死亡以及脑卒中的发生风险等方面的作用与氯吡格雷相当,但该药会增加患者主要出血、次要出血事件的发生风险。 相似文献
9.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(8):e474-e484
BackgroundIn countries where frontline drug approval is limited to first-generation proteasome inhibitors or immunomodulatory drugs, relapses have been both more frequent and less durable. We investigated real world data on the efficacy and safety of daratumumab monotherapy among patients with relapsed refractory multiple myeloma (RRMM) from Turkey using a prospective early access program.Patients and MethodsA total of 42 patients with RRMM after a minimum of 3 previous lines of proteasome inhibitor/immunomodulatory drug-based treatments were included from 25 centers across Turkey. Daratumumab monotherapy was administered intravenously at a dose of 16 mg/kg weekly (cycles 1-2), on alternate weeks (cycles 3-6), and monthly thereafter.ResultsThe median daratumumab monotherapy duration was 5.5 months (range, 0.2-28.7 months). The overall response rate was 45.2%, including 14 (33.3%) partial responses, 4 (9.5%) very good partial responses, and 1 (2.4%) complete response. The median duration of response was 4.9 months. The median progression-free survival (PFS) was 5.5 (95% confidence interval, 2.6-8.4 months) with 12- and 18-month PFS rates of 35.7% and 31.0%, respectively. The median overall survival was not reached; the 12- and 18-month overall survival rates were 64.3% and 59.5%, respectively. The depth of response had a significant effect on PFS (log-rank test, P = .026). Overall, of the 76 adverse events reported, 33 (43.4%) were grade ≥ 3; only 4 (9.52%) were grade 3 infusion-related reactions. No infusion-related reactions or adverse events led to treatment discontinuation.ConclusionThe present findings from our daratumumab early access program have confirmed the efficacy and safety profile of daratumumab monotherapy in heavily pretreated Turkish patients with RRMM. 相似文献
10.
《Vaccine》2022,40(2):255-265
The high mutation rate of infectious bronchitis virus (IBV) poses a significant threat to the protective efficacy of vaccines. This study aimed at analyzing the S1 genes of IBV field strains isolated in Southwestern China from 2018 to 2020, assessing the pathogenicity of four dominating strains, and evaluating the protective efficacy of four commercial vaccine strains against the endemic representative strains. Thirty-two field strains of IBV were isolated in Southwestern China from 2018 to 2020. Phylogenetic analysis of their S1 genes revealed the nucleotide homology ranged from 64.6% to 100%, and belonged to five genotypes [GI-19 (QX, 53.13%), GI-28 (LDT3-A,15.63%), GI-7 (TW, 12.50%), GI-1 (Mass, 6.23%), GVI-1 (TC07-2, 6.25%)], and two variant groups [variant-3 (3.13%) and variant-5 (3.13%)]. Recombination events between field and vaccine strains or between field strains were identified in the S1 genes of eight IBV field strains. The CK/CH/YNKM/191128 and CK/CH/CQBS/191203 strains of GI-19 showed morbidity rates of 66.7% and 73.7%, respectively, and mortality rates of 13.3% and 33.3%, respectively. Besides, the CK/CH/SCYC/191030 and CK/CH/GZGY/191021 strains of GI-28 caused morbidity rates of 60% and 86.7%, respectively, and mortality rates of 33.3%. The protective efficacy of the four commercial live vaccine strains (4/91, FNO-E55, LDT3-A, and QXL87) ranged from 70% ? 100% and reduced tissue lesions against CK/CH/GZGY/191021 and CK/CH/CQBS/191203 strains. LDT3-A strain was the most effective one but still could not completely prohibit IBV shedding. These findings provide a reference for IBV molecular evolution analysis and control of IB. 相似文献